Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms

Russo, Ethan B.; Cuttler, Carrie; Cooper, Ziva D.; Stueber, Amanda; Whiteley, Venetia L; Sexton, Michelle

doi:10.1089/can.2021.0058

Cited by 25 publications

(27 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We assessed past-year cannabis, CBD, Δ8-THC, CBG, and CBN use and whether participants had heard of emerging cannabinoids in the past year (eAppendix in Supplement 1). These cannabinoids were selected based on recently published clinical reports . Using logistic regression models, we investigated associations of demographic and cannabis use characteristics with any emerging cannabinoid use and Δ8-THC use.…”

Section: Methodsmentioning

confidence: 52%

Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults

Wilson-Poe,

Smith,

Elliott

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 52%

Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults

Wilson-Poe,

Smith,

Elliott

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

“…CBD and CBG were found to be the most potent at decreasing cell viability with IC50 values within the low µm range in all three cell lines. Both these compounds do not appear to have THC-like intoxicating effects which makes them more favourable candidates for therapeutic development [ 11 ]. Hence, we focused on CBD and CBG to more comprehensively explore their anti-cancer potential and modes of action.…”

Section: Discussionmentioning

confidence: 99%

“…Cannabis contains over 100 plant-derived cannabinoids (phytocannabinoids), including the main psychoactive constituent ∆ 9 -tetrahydrocannabinol (THC) and the non-intoxicating compound cannabidiol (CBD). Although CBD and THC are the most studied, there is growing interest in the therapeutic potential of other phytocannabinoids, for example cannabigerol (CBG) and cannabidiolic acid (CBDA) [ 8 , 9 , 10 , 11 , 12 ]. The majority of research has focused on the use of THC in the symptomatic management of cancer due to its appetite stimulatory, analgesic, and anti-emetic effects [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma

Colvin

Hudson

Anderson

et al. 2022

Cancers

View full text Add to dashboard Cite

Mesothelioma is an aggressive cancer with limited treatment options and a poor prognosis. Phytocannabinoids possess anti-tumour and palliative properties in multiple cancers, however their effects in mesothelioma are unknown. We investigated the anti-cancer effects and potential mechanisms of action for several phytocannabinoids in mesothelioma cell lines. A panel of 13 phytocannabinoids inhibited growth of human (MSTO and H2452) and rat (II-45) mesothelioma cells in vitro, and cannabidiol (CBD) and cannabigerol (CBG) were the most potent compounds. Treatment with CBD or CBG resulted in G0/G1 arrest, delayed entry into S phase and induced apoptosis. CBD and CBG also significantly reduced mesothelioma cell migration and invasion. These effects were supported by changes in the expression of genes associated with the cell cycle, proliferation, and cell movement following CBD or CBG treatment. Gene expression levels of CNR1, GPR55, and 5HT1A also increased with CBD or CBG treatment. However, treatment with CBD or CBG in a syngeneic orthotopic rat mesothelioma model was unable to increase survival. Our data show that cannabinoids have anti-cancer effects on mesothelioma cells in vitro and alternatives of drug delivery may be needed to enhance their effects in vivo.

show abstract

“…For example, preclinical evidence shows the acid precursor cannabidiolic acid (CBDA) may be helpful for stress and anxiety, 55 while the cannabinoid cannabigerol (CBG) was self-reported to improve sleep, anxiety, depression, and pain in humans. 56 Terpenes such as myrcene, linalool, and beta-caryophyllene also may have sedative or anxiolytic effects. [57][58][59][60][61] Improved sleep and anxiety may help improve mood and general well-being, which may reduce harm.…”

Section: Considerations For Current Evidencementioning

confidence: 99%

Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review

Lo,

MacCallum,

Nanson

et al. 2023

Can J Psychiatry

View full text Add to dashboard Cite

Objective The drug poisoning crisis throughout North America necessitates novel harm reduction approaches. Emerging evidence suggests that cannabidiol (CBD) may have some utility as a harm reduction modality for those with problematic substance use. This rapid review aimed to synthesize available evidence on CBD as a potential harm reduction tool for people who use drugs while providing clinical and research insights. Method A systematic search in EMBASE, MEDLINE, CENTRAL, and CINAHL was completed in July 2022. For inclusion, studies had to meet the following criteria: (1) drawn from an adult population of people who use drugs; (2) investigates CBD as an intervention for problematic substance use or harm reduction–related outcomes; (3) be published after the year 2000 and in English; and (4) be primary research or a review article. A narrative synthesis was used to group outcomes relevant to harm reduction and provide clinical and research insights. Results We screened 3,134 records, of which 27 studies (5 randomized trials) were included. The evidence remains limited, but available studies support the potential utility of CBD to reduce drug-induced craving and anxiety in opioid use disorder. There were low-quality studies suggesting that CBD may improve mood and general well-being of people who use drugs. Evidence suggests that CBD monotherapy may not be an adequate harm reduction strategy for problematic substance use but rather an adjunct to the standard of care. Conclusion Low-quality evidence suggests that CBD may reduce drug cravings and other addiction-related symptoms and that CBD may have utility as an adjunct harm reduction strategy for people who use drugs. However, there is a significant need for more research that accurately reflects CBD dosing and administration regimens used in a real-world context.

show abstract

Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms

Cited by 25 publications

References 71 publications

Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults

Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults

An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma

Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review

Contact Info

Product

Resources

About